Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond

Clin Cancer Res. 2023 Sep 15;29(18):3563-3565. doi: 10.1158/1078-0432.CCR-23-1658.

Abstract

KRAS-mutated non-small cell lung cancer (NSCLC) is the most common genetically altered subtype of NSCLC, yet targeted therapies remain limited. Multiple studies have investigated combinations of MEK inhibitors with chemotherapy without success. Here we discuss these studies and novel approaches to targeting KRAS-mutated NSCLC. See related article by Gadgeel et al., p. 3641.

Publication types

  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Docetaxel / therapeutic use
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation
  • Neoplasm Recurrence, Local
  • Proto-Oncogene Proteins p21(ras) / genetics

Substances

  • Docetaxel
  • trametinib
  • Proto-Oncogene Proteins p21(ras)
  • KRAS protein, human